[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eravacycline\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eravacycline":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100567346","real-world-pharmacokineticpharmacodynamic-study-of-eravacycline-in-critically-iii-patients-100567346",false,"NCT06666998","Real-World Pharmacokinetic\u002FPharmacodynamic Study of Eravacycline in Critically III Patients","Inclusion Criteria:\n\n* Adult male or female aged 18-75 years\n* Not respond to initial empirical treatment, treatment time to reach Eravacycline steady-state concentration\n* Empirical antimicrobial treatment is ineffective\n* Eravacycline application for ≥ 3 days\n* Understand and sign informed consent\n\nExclusion Criteria:\n\n* Urinary tract infection\n* Allergic to Eravacycline, Tigecycline antibiotics or any excipients or have previously experienced serious adverse reactions\n* Any unstable or potentially endangering the safety of the subject and their compliance with the study as judged by the investigator; comorbidities or social circumstances that can make the subject unable to follow the study plan or even endanger the safety of the patient\n* Patients expected to survive for no longer than 48h.","ALL","18 Years","75 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the efficacy of Eravacycline in the treatment of patients with bacterial infection and to assess the pharmacokinetics of Eravacycline and to establish a population pharmacokinetic model of Eravacycline.",[24,25,26,27,28],"Eravacycline","Pharmacokinetics","Bacteria Infection","Bacterial Resistance to Antimicrobial","Empirical Antimicrobial Therapy","NOT_YET_RECRUITING","2024-11-01",{"date":32,"type":33},"2024-11-04","ACTUAL",{"date":30,"type":20},{"date":36,"type":20},"2026-11-01",{"name":38,"class":39},"Sichuan Provincial People's Hospital","OTHER"]